Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lisa Takagi

 

Lisa is based in Tokyo as a managing editor and will be providing editorial coverage of all aspects of Japan’s prescription drug market for Scrip and the Pink Sheet, including company, market, pricing and regulatory developments, as well as helping to further expand our original content in the region through interviews and unique stories. In the longer term, the intention is for Lisa to support, along with the rest of the content team, our broader regional push towards more local-language content, use of multimedia, and thought leadership initiatives.

Lisa brings close to a decade of experience working in either international teams or reporting, writing and editing, including in broadcast media through an internship as a TV reporter in Canada. Most recently, she was covering another fast-moving, high-tech sector, IT, for ITmedia Enterprise in Japan, where several of her stories won quarterly “Best Content” awards and helped significantly expand readership.

Lisa holds an MA in Fine Art from Tokyo University of the Arts as well as a Master’s in Journalism from the University of King’s College in Halifax, Canada. She is native level bilingual in Japanese and English and also has conversational ability in Mandarin and French. Her interests and hobbies outside work include taking monochrome photos with digital/film cameras and visiting museums.

Latest From Lisa Takagi

Japan Q1 Roundup: Enhertu, Padcev, Actemra and Lenvima Push Growth

The main Japanese pharma players report a generally strong fiscal Q1, helped by mainstays including Daiichi Sankyo's Enhertu, Astellas's Xtandi and Padcev and Chugai's Actemra, and in some cases by the weaker yen. 

Japan Business Strategies

Kyorin Pharma To Shut Down US Subsidiary ActivX

Kyorin Pharma is to end operations at its US subsidiary ActivX 18 years since its acquisition. Although the California firm’s kinase-probing technology has contributed to Kyorin’s R&D, the Japanese firm acknowledged limits to future applicability in the development of candidate compounds.

Business Strategies Research & Development

APAC Regulatory Roundup: Infectious Disease A Common Theme As COVID Lingers

A roundup of key regulatory and policy developments in the Asia-Pacific in the first half of the year reveals broad developments across the region's diverse markets, although there seemed to be a common thread - a renewed focus on infectious diseases amid the lingering impact of the pandemic and the emergence of new threats.

Asia Pacific Infectious Diseases

Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta

Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.

Deal Watch Business Strategies

Japan’s All-Genome Project Hopes To Push Pharma R&D

Japan is aiming for the betterment of pharma R&D and medical services for rare disease patients by building a database connecting genome analysis data and clinical records. While several clinical studies are planned for the next couple of years, there are also concerns around the actual trickle-down of benefits to patients and data privacy.

Japan Rare Diseases

Asia Deal Watch: Rona Takes On Sanofi’s siRNA Platform

Rona hopes technology acquired from Sanofi will enhance its RNA capabilities in liver and non-liver indications. NeuroFront gets Greater China and Singapore rights to Novaremed’s neuropathic pain drug.

Deal Watch Business Strategies
See All
UsernamePublicRestriction

Register